Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection

• Status: Withdrawn
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Indication : Treatment of Subject with COVID-19 infection Phase : Phase I Duration of Study :

12 day Sample size : at least 15 subjects Methodology : Classical 3+3 design Investigational Product : MPT0B640, 15, 30, 60, 80 and 100mg, oral suspension Study Objective

1. Primary Objective To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640

2. Secondary Objectives To evaluate the safety and tolerability of MPT0B640 during entire study period To assess the efficacy of MPT0B640 To characterize the 48 hours PK of MPT0B640

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: J Ints Bio; Joseah Bio

Criteria

Inclusion Criteria:

Subjects must meet all inclusion criteria as listed below:

1. Age ≥18 years at time of signing Informed Consent Form

2. Laboratory (quantitative Polymerase Chain Reaction, qPCR) confirmed infection with 2019-nCoV.

3. Lung involvement confirmed with chest imaging

4. Hospitalized with a SaO2/SPO2≤94% on room air or PaO2/FiO2 ratio <300mgHg

5. ≤7 days since illness onset

6. Must agree not to enroll in another study of an investigational agent prior to completion of Day 12 of study.

Exclusion Criteria:

1. Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.

2. Severe liver disease (e.g. Child Pugh score ≥ C, AST>5 times upper limit)

3. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination

4. Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis

5. Will be transferred to another hospital which is not the study site within 72 hours.

6. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation.